Northland Securities analyst Suraj Kalia maintained a Buy rating on Insulet Corp (PODD) today and set a price target of $100. The company’s shares opened today at $93.42.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 13.8% and a 59.9% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Strata Skin Sciences Inc, and Obalon Therapeutics Inc.
Insulet Corp has an analyst consensus of Moderate Buy, with a price target consensus of $102, implying a 9.2% upside from current levels. In a report issued on February 19, Canaccord Genuity also reiterated a Buy rating on the stock with a $100 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $108.91 and a one-year low of $70.80. Currently, Insulet Corp has an average volume of 689.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insulet Corp. is an innovative medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Billerica, MA.
